Skip to main content

Table 3 Influence of age and gender on comorbidities

From: The age again in the eye of the COVID-19 storm: evidence-based decision making

  Age Gender
< 30 30–45 45–60 60–75 > 75 Male Female
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Hypertensiona
 No 7(5.6) 19(15.2) 41(32.8) 41(32.8) 17(13.6) 67(53.6) 58(46.4)
 Yes 0(0) 2(1.7) 17(14) 45(37.2) 57(47.1) 73(60.3) 48(39.7)
Dyslipidaemiaa
 No 7(4.9) 17(11.9) 45(31.5) 47(32.9) 27(18.9) 81(56.6) 62(43.4)
 Yes 0(0) 4(3.9) 15(14.7) 38(37.3) 45(44.1) 59(57.8) 43(42.2)
Obesity
 No 5(3) 14(8.4) 42(25.1) 56(33.5) 50(29.9) 103(61.7) 64(38.3)
 Yes 1(2.9) 2(5.9) 7(20.6) 18(52.9) 6(17.6) 17(50) 17(50)
Diabetesa
 No 7(3.9) 18(10.1) 55(30.9) 57(32) 41(23) 102(57.3) 76(42.7)
 Yes 0(0) 3(4.4) 5(7.4) 31(45.6) 29(42.6) 40(58.8) 28(41.2)
Smokera,b
 No 4(2.2) 17(9.1) 50(26.9) 65(34.9) 50(26.9) 101(54.3) 85(45.7)
 Yes 3(12) 1(4) 7(28) 6(24) 8(32) 20(80) 5(20)
 Ex 0(0) 0(0) 0(0) 8(80) 2(20) 8(80) 2(20)
Primary immunodeficiencya
 No 7(3) 21(9) 59(25.3) 83(35.6) 63(27) 133(57.1) 100(42.9)
 Yes 1(50) 0(0) 0(0) 0(0) 1(50) 1(50) 1(50)
Secundary immunodeficiency
 No 5(2.7) 16(8.6) 52(28.1) 60(32.4) 52(28.1) 98(53) 87(47)
 Yes 2(4.9) 3(7.3) 6(14.6) 21(51.2) 9(22) 28(68.3) 13(31.7)
Epidemiological background
 NHR 1(2.8) 3(8.3) 6(16.7) 8(22.2) 18(50) 18(50) 18(50)
 LIR 1(1.9) 5(9.6) 15(28.8) 16(30.8) 15(28.8) 31(59.6) 21(40.4)
 FW 1(7.1) 1(7.1) 7(50) 4(28.6) 1(7.1) 5(35.7) 9(64.3)
 CT 3(6.7) 7(15.6) 12(26.7) 23(51.1) 13(51.1) 38(65.5) 20(34.5)
  1. All p-values either agea or genderb were < 0.001
  2. Abbreviations: NHR Nursing home resident, LIR Live-in relative, FW Frontline worker, CT Community transmission